HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identified via HitGen's DEL technology platform, has advanced into a Phase 2 proof-of-concept trial for cardiovascular risk reduction. The QUELL-CV trial is...
BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identified via HitGen's DEL technology platform, has advanced into a Phase 2 proof-of-concept trial for cardiovascular risk reduction. The QUELL-CV trial is...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.